
Tecentriq-Avastin combo hits endpoint in liver cancer
Data from 501 treatment-native HCC patients enrolled in the open label IMbrave150 Phase III study demonstrated a incremental improvement...

UniQure looking to raise US$200m
The Amsterdam-based company announced that it had commenced an underwritten public offering of US$200m of its ordinary shares. uniQure also intends...

Rotavirus vaccines kill cancer cells
The team headed by Aurelian Marabelle discovered in mice that commercially available vaccines against rotavirus – which causes diarrhea in children...

Meatable NV raises US$10m in seed funding
BlueYard Capital, the Eurostars Programme of the European Commission, and angel VCs Taavet Hinrikus and Albert Wenger (Union Square Ventures)...

Lundback swallows migraine drug maker Alder
Alder's first-in-class monoclonal antibody for migraine prevention, eptinezumab, targets the calcitonin gene-related peptide and faces FDA...

BIOncoTech Therapeutics and MSD combine cancer drugs
The clinical collaboration aims at providing clincial Phase II evidence that Bioncotech Therapeutics’ RNA–based cancer lead BO-112 can improve the...

Zealand Pharma acquires Encycle
Under the agreement, Zealand Pharma A/S will acquire all outstanding shares in Encycle Therapeutics Inc., and all its intellectual property,...